HOOKIPA Announces Changes to its Board of Directors – Resignation of Sander van Deventer
June 19 2020 - 7:00AM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapeutics targeting infectious diseases and
cancers based on its proprietary arenavirus platform, today
announced that Dr. Sander van Deventer has resigned as a
Non-Executive Director of the Company’s Board of Directors and
Audit Committee.
Sander van Deventer, who joined the Board of
Directors in 2011, will continue to serve as a member of HOOKIPA’s
Scientific Advisory & Review Committee.
Dr. Jan van de Winkel, Chairman of the Board of
Directors at HOOKIPA, said: “On behalf of my fellow Board
members and HOOKIPA's executive team, I would like to thank Sander
for his major contributions to building our company. His extensive
experience and creative insights played an important part in our
development and he leaves with our very best wishes for the
future.”
HOOKIPA’s Board of Directors will now consist of
8 members, including Dr. Jan van de Winkel as Chairman, Michael A.
Kelly, Dr. David R. Kaufman, Dr. Christoph Lengauer, Julie O’Neill,
Graziano Seghezzi, Joern Aldag, and Reinhard Kandera.
About
HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical
stage biopharmaceutical company developing a new class of
immunotherapeutics targeting infectious diseases and cancers based
on its proprietary arenavirus platform that is designed to
reprogram the body’s immune system.
HOOKIPA’s proprietary arenavirus-based
technologies, VaxWave®, a replication-deficient viral vector, and
TheraT®, a replication-attenuated viral vector, are designed to
induce robust antigen specific CD8+ T cells and
pathogen-neutralizing antibodies. Both technologies are designed to
allow for repeat administration to augment and refresh immune
responses. TheraT® has the potential to induce CD8+ T cell response
levels previously not achieved by other immuno-therapy approaches.
HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in
vivo to activate the immune system.
HOOKIPA’s VaxWave®-based prophylactic
Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2
clinical trial in CMV-negative patients awaiting kidney
transplantation from living CMV-positive donors as well as
CMV-positive patients awaiting kidney transplantation from
CMV-positive or -negative donors. To expand its infectious disease
portfolio, HOOKIPA has entered into a collaboration and licensing
agreement with Gilead Sciences, Inc. to jointly research and
develop functional cures for HIV and chronic Hepatitis B
infections.
In addition, HOOKIPA is building a proprietary
immuno-oncology pipeline by targeting virally mediated cancer
antigens, self-antigens and next-generation antigens. The TheraT®
based lead oncology product candidates, HB-201 and HB-202, are in
development for the treatment of Human Papilloma Virus 16-positive
cancers. The Phase 1/2 clinical trial for HB-201 was initiated in
December 2019. The HB-202 IND application was cleared by the FDA in
June 2020.
Find out more about HOOKIPA online at
www.hookipapharma.com.
For further
information, please contact: |
|
|
|
Media |
Investors |
Nina Waibel |
Matt Beck |
Senior Director - Communications |
Executive Director - Investor Relations |
nina.waibel@hookipapharma.com |
matthew.beck@hookipapharma.com |
|
|
Media enquiries |
|
Instinctif Partners |
|
hookipa@instinctif.com |
|
+44 (0)20 7457 2020 |
|
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Apr 2023 to Apr 2024